Key Highlights

  • Varex Imaging (VREX) surged 48% pre-market and closed around $18.46 on Monday after Teledyne agreed to acquire the company for $18.90 a share in cash.
  • The Offer Price sits above every prior analyst target on the stock and above its 52-week high, ending nine years of Varex trading below its potential as an independent spin-off.
  • Third-quarter Revenue of $210.5 million rose 3.7% but missed analyst expectations, though non-GAAP Earnings of $0.31 a share beat consensus of $0.20 comfortably.
  • The deal carries no financing condition, but requires Shareholder and regulatory approval, with a guided close in early 2027 and a long outside date that hints at scrutiny of Varex's China exposure.

Nine Years of Drift, Resolved in One Morning

Varex Imaging (NASDAQ:VREX) closed at $12.41 on Friday, 7 August. By Monday's open it was at $18.40, up 48% before the bell, and it finished the session around $18.46, a whisker under the $18.90 that Teledyne Technologies has agreed to pay. The 52-week range tells the story better than the percentage does: the low was $9.09 and Monday's high of $18.49 was the top of it. Teledyne is buying the company for more than it has been worth at any point in the past twelve months.

For long-term holders the context is bleaker still. Varex was separated from Varian Medical Systems in a tax-free spin-off completed at the end of January 2017, listing on Nasdaq as the components half of a Business whose more glamorous half, oncology systems, went on to be bought by Siemens Healthineers for $16.4 billion. The X-ray parts business never commanded that kind of affection. It went into Monday with a Market Value of roughly $520 million on a company turning over $865 million a year.

Why the Shares Were So Cheap

The immediate reason was a poor 2025. Varex reported fiscal 2025 revenue of $844.6 million, up 4%, but a net loss of $69.9 million after a $93.9 million Goodwill Impairment charge that ran operating expenses up 42%. That is the kind of write-down that tends to reset how the market thinks about a company's growth assumptions.

Underneath sat a set of exposures investors had learned to discount. Varex sells into China at scale, and the country is central to its plan to Supply CT components, a strategic strength during a Trade War and a valuation penalty at the same time. Tariffs hit directly: the company paid duties and only recovered $17 million from customs authorities in the quarter just reported. Its Balance Sheet carried a convertible note that had to be refinanced through senior secured notes due October 2027, with $200 million repaid during the fiscal year. A further refinancing in March this year left gross Debt at $351 million and cut interest costs, but it also drained cash, with the balance falling from $155 million at fiscal year end to $88 million by the second quarter.

Chief executive Sunny Sanyal had, in fairness, been arguing the operating picture was improving. On the May call the company reinstated full-year guidance of $860 million to $880 million in revenue and non-GAAP earnings of $0.80 to $1.00 a share, and said Chinese revenue had grown 8% year over year with Demand normalizing. The market did not pay for it.

Tubes, Detectors and a Very Short Customer List

What Teledyne is buying is one of the two or three serious independent suppliers of X-ray sources and digital detectors on the planet. Varex builds more than 27,000 X-ray tubes and 20,000 detectors a year across eight countries, with an installed base of over 160,000 tubes. Medical accounted for $134 million of the $210.5 million in third-quarter revenue; industrial applications including cargo screening, non-destructive testing and food inspection supplied the other $77 million and has been the faster-growing, higher-margin half.

The commercial catch is concentration. In fiscal 2025 the top five customers, including Canon and Siemens, delivered 40% of revenue, and a single customer accounted for 18%. Varex does not sell to hospitals directly; it sells to the handful of companies that build the scanners hospitals buy. That structure caps pricing power and makes any single equipment maker's inventory cycle a company-wide event. It is also why Varex has an interesting asset in photon-counting detectors, where management said two CT equipment customers were developing systems and eight further engagements were running in non-CT applications.

The Quarter Nobody Talked About

Varex published third-quarter results on the same morning as the deal and then canceled its earnings call, declining to give guidance because of the pending transaction. The numbers deserved more attention than they got. Revenue of $210.5 million rose 3.7% but fell short of the roughly $215.5 million analysts expected. Non-GAAP earnings of $0.31 a share beat a $0.20 consensus comfortably, and adjusted EBITDA of $33.1 million was up 20.4%. Non-GAAP gross Margin reached 37%.

Part of that beat was one-off: the customs refund of $17 million was partly offset by a $7 million revenue reduction for expected customer reimbursements, leaving roughly $10 million of Gross Profit benefit. Strip it out and the quarter was solid rather than transformative, a reasonable summary of Varex's last three years, and a reasonable explanation of why the board took a cash exit.

What Now Has to Happen

Shareholders will vote at a special meeting once Varex files its proxy statement, and the Merger agreement contains no financing condition, so Teledyne's ability to pay is not in question. Regulatory approvals are required, and the parties have guided to a close in early 2027. The outside date is 10 May 2027, with an extension available to 10 August 2027, a long runway that hints at non-U.S. reviews, with Varex's China business the obvious candidate.

If the board accepts a superior proposal, Varex owes Teledyne a $25.3 million termination fee, a relatively low hurdle that in theory leaves the door ajar for another bidder, though none has surfaced. Executives stand to benefit either way: regulatory filings disclose aggregate equity-award payouts of $8.7 million to Sanyal, $2.8 million to finance chief Sam Maheshwari and $1.4 million each to two other named officers.

Conclusion

Analysts responded by getting out of the way, with several moving to neutral or hold ratings; the pre-deal average target was $17.40, below the offer price. Some shareholders are reportedly exploring litigation over whether the price is adequate, which is routine in U.S. takeovers and rarely changes terms. That leaves a roughly 2.5% gross spread and a wait of perhaps six months, a thin return for the risk that a Chinese regulator, an antitrust theory about overlapping detector lines, or a downturn in Varex's customers' order books gives Teledyne room to walk. If the deal breaks, the reference point is $12.41, and the reasons the shares traded there have not gone away.